Add BrightSurf on Google Email

Social rejection could drive people to take COVID-19 safety precautions, new research finds

New research reveals that social rejection can drive individuals to prioritize disease protection. When people experience social pain, they become more likely to take concerted efforts to safeguard against COVID-19. Conversely, when social interactions are less painful, people may be less vigilant in protecting themselves.

SourceSociety for Personality and Social Psychology·JournalSocial Psychological and Personality Science·TypeExperimental study·DateAug 11, 2022

A new way to detect infection

Scientists have discovered a new way to detect infection by sensing physical forces produced by bacterial invasion. Cells use mechanosensor protein PIEZO1 to detect changes in surface tension, triggering an early and fast immune response.

SourceUmea University·JournalCell Reports·DateAug 9, 2022

Immune boosting benefits of tuberculosis vaccine seen in infants more than a year after vaccination

A new study has shown that the TB vaccine can produce a long-lasting 'trained immunity response' in infants, lasting more than 14 months after vaccination. The research found that the BCG vaccine's off-target effects on the immune system can lead to reprogramming of genes in a specific blood cell type, known as monocytes.

SourceMurdoch Childrens Research Institute·JournalScience Advances·TypeRandomized controlled/clinical trial·DateAug 5, 2022

Reinvigorating ‘lost cause’ exhausted T cells could improve cancer immunotherapy

Researchers at the University of Pittsburgh have discovered that even terminally exhausted T cells retain some capacity to function again. They identified approaches to overcome exhaustion by targeting co-stimulation pathways and reprogramming T cells to be resistant to hypoxia, a common tumor microenvironmental signal.

SourceUniversity of Pittsburgh·JournalScience Immunology·TypeExperimental study·DateAug 5, 2022

Destroying tumor cells: Targeted immunotherapy using injectable materials

Researchers at TIBI developed a minimally invasive method for targeted delivery of immunotherapeutic treatments, resulting in slower tumor growth and higher activation of T-cells. The injectable gelatin biomaterial containing silicate nanoplatelets showed sustained drug release and controlled ICI delivery.

SourceTerasaki Institute for Biomedical Innovation·JournalACS Applied Materials & Interfaces·TypeExperimental study·DateAug 1, 2022

The gut patrol

Scientists at La Jolla Institute for Immunology discover how gut barrier cells send secret messages to patrolling T cells, keeping them alive and active. The study sheds light on conditions like inflammatory bowel disease and highlights the importance of HVEM protein in maintaining a healthy gut microbiome.

SourceLa Jolla Institute for Immunology·JournalScience Immunology·TypeExperimental study·DateJul 29, 2022

Bacterial bullseye

A team of researchers connected the dots for one important gut bacterium, revealing its molecular structure and function in the immune system. The study found that Akkermansia muciniphila's lipid activates toll-like receptors, triggering the release of certain cytokines while leaving others alone.

SourceHarvard Medical School·JournalNature·TypeExperimental study·DateJul 27, 2022

CRISPR therapeutics can damage the genome

A new study from Tel Aviv University found that CRISPR therapeutics can lead to a significant loss of genetic material in treated cells, potentially destabilizing the genome and promoting cancer. The researchers detected up to 10% of cells with lost chromosomes, highlighting the need for extra care when using this technology.

SourceTel-Aviv University·JournalNature Biotechnology·DateJul 24, 2022

Light shed on SARS-CoV-2 replication in bat cells

Researchers at the Institut Pasteur and CNRS studied SARS-CoV-2 replication in bat cells, finding that viral infection triggers a powerful immune response that prevents the virus from replicating. The study uses real-time imaging techniques to visualize the speed of cell infection and the formation of syncytia.

SourceInstitut Pasteur·JournalJournal of Virology·TypeExperimental study·DateJul 19, 2022

Anti-rejection medication and immunotherapy kicks cancer and protects kidney transplants

Researchers at the University of South Australia have discovered that combining anti-rejection medication with immune checkpoint inhibitors can significantly reduce the risk of organ rejection and eliminate cancer cells in a quarter of patients. The study involved 22 patients with renal transplants and incurable locally advanced or met...

SourceUniversity of South Australia·JournalThe Lancet Oncology·TypeExperimental study·DateJul 18, 2022

Scientists identify what makes the Delta variant dangerous and explain the recent surge in COVID-19 infections

Researchers analyze delta variant's biophysical characteristics, revealing unique traits that evade neutralizing antibodies and contribute to severe symptoms. The study sheds light on why vaccinated individuals can still contract the virus and why delta variant hospitalizations are higher than other variants.

SourceUniversity of Colorado Anschutz Medical Campus·JournalJournal of Molecular Biology·DateJul 18, 2022

SARS-Arena reveals hidden hooks in virus

The SARS-Arena program identifies conserved peptides in the SARS-CoV-2 virus that could be used to develop vaccines. The peptides are part of the nucleocapsid protein, which is highly expressed upon infection and highly immunogenic.

SourceRice University·JournalFrontiers in Immunology·TypeData/statistical analysis·DateJul 13, 2022

Climate change is making plants more vulnerable to disease. New research could help them fight back

New research reveals that specific proteins in plant cells explain why plant defenses falter under high temperatures, leaving them susceptible to infections. Scientists have also discovered a way to reverse this effect by constantly activating the CBP60g master switch gene, which bolsters plant defenses without stunting growth.

SourceDuke University·JournalNature·TypeExperimental study·DateJun 29, 2022

UTHealth Houston study: Flu vaccination linked to 40% reduced risk of Alzheimer’s disease

A new study from UTHealth Houston found that flu vaccination was associated with a 40% lower risk of developing Alzheimer’s disease in US adults over a four-year period. The study analyzed a large sample of patients and found that consistent flu vaccination every year had the strongest protective effect.

SourceUniversity of Texas Health Science Center at Houston·JournalJournal of Alzheimer’s Disease·DateJun 24, 2022

Females far likelier to suffer with Long COVID, a new review of studies shows, underscoring a critical need for sex-disaggregated research

Researchers analyzed data from over 1.3 million patients and found females experience ear, nose, and throat issues, mood disorders, and fatigue, while males are more likely to suffer from renal disorders. Sex-disaggregated research is crucial for effective therapies and public health interventions.

SourceTaylor & Francis Group·JournalCurrent Medical Research and Opinion·TypeLiterature review·DateJun 21, 2022

New treatment option shows promise in clearing HPV infection

A Phase II study published in Frontiers in Oncology found that daily use of AHCC supplementation may help most patients eliminate their HPV infection and decrease the risk of HPV-related cancers. The study showed that 14 of 22 patients (63.6%) became HPV-negative, suggesting a potential treatment option for persistent HPV infections.

Rethinking the rabies vaccine

Scientists have discovered a new, high-resolution view of the rabies virus glycoprotein, which could lead to more effective vaccines. The study's findings suggest that a better-shaped vaccine could provide lifelong protection against the deadly disease.

SourceLa Jolla Institute for Immunology·JournalScience Advances·TypeExperimental study·DateJun 17, 2022

More than one way to skin a tumor

Researchers at Kyoto University identified the mechanism behind active inflammation and immunosuppression in tumor microenvironments. EP2/EP4 inhibitors suppress tumor growth by allowing regulatory T cells to infiltrate and activate within tumors, benefiting patients with certain cancers.

SourceKyoto University·JournalCell Reports·TypeExperimental study·DateJun 16, 2022

Chinese Medical Journal Review shines a light on the overlooked virus, hepatitis D

Researchers discuss Hepatitis D's life cycle and interactions with its host, exploring strategies for further research to combat this overlooked virus. HDV coinfects people with hepatitis B, rapidly progressing to liver cirrhosis and cancer if left untreated, with a review published in the Chinese Medical Journal.

SourceCactus Communications·JournalChinese Medical Journal·TypeLiterature review·DateJun 16, 2022

Greater understanding of immune signalling molecule raises hope for improved clinical use

A detailed understanding of interleukin 2's role in the immune system has been gained through a new mouse model, enabling scientists to identify potential new uses as an immune-modulating biologic drug. This breakthrough may lead to optimized autoimmune and cancer treatment while avoiding unwanted side effects.

SourceBabraham Institute·JournalJournal of Experimental Medicine·TypeExperimental study·DateJun 14, 2022

Higher rate of COVID-19 death before vaccination linked to certain common inflammatory immune conditions

A study analyzing 17 million patient GP records in England found that people with certain inflammatory immune conditions were at higher risk of dying or needing hospital care from COVID-19. The analysis suggests that targeting prevention strategies and early interventions towards those most at risk can help inform evidence-based policy.

SourceLondon School of Hygiene & Tropical Medicine·JournalThe Lancet Rheumatology·DateJun 8, 2022

Targeted micronutrition ameliorates allergy symptoms

Researchers at the Messerli Research Institute developed a lozenge that compensates for micronutrient deficiencies in immune cells, reducing inflammation and allergic reactions. The study showed a 45% reduction in symptom burden during peak pollen season, presenting a new approach to allergy care.

SourceMedical University of Vienna·JournalThe Journal of Allergy and Clinical Immunology In Practice·DateJun 7, 2022

LSU Health study shows promise of NB-UVB phototherapy in hospitalized COVID-19 patients

A randomized, placebo-controlled pilot study found that NB-UVB phototherapy decreased mortality in hospitalized COVID-19 patients with no adverse events reported. The treatment was effective in both vaccinated and unvaccinated patients, with reduced pathologic inflammation and improved intracellular killing of pathogens.

SourceLouisiana State University Health Sciences Center·JournalExperimental Dermatology·TypeRandomized controlled/clinical trial·DateJun 3, 2022

Promising results for chemo-immunotherapy combination against pancreatic cancer, Penn study finds

Researchers found that combining chemotherapy with immunotherapy increased one-year survival rates for patients with advanced pancreatic cancer, with anti-PD-1/chemo regimen showing the highest response. The study identified key immune system biomarkers associated with better outcomes, offering new hope for precision oncology.

SourceUniversity of Pennsylvania School of Medicine·JournalNature Medicine·TypeObservational study·DateJun 3, 2022

“Masked” cancer drug sneaks through body to deliver anti-tumor treatment with fewer side effects

Researchers at the University of Chicago's Pritzker School of Molecular Engineering have developed a version of interleukin-12 that is activated only when it reaches a tumor, reducing side effects. The new 'masked' molecule has shown promising results in eliminating cancer cells and outperforming existing immune therapies.

SourceUniversity of Chicago·JournalNature Biomedical Engineering·DateJun 1, 2022

Nerve stimulation promotes resolution of inflammation

Researchers at Karolinska Institutet discovered that electrical stimulation of the vagus nerve promotes healing in acute inflammation by shifting the balance between inflammatory and anti-inflammatory molecules. This finding opens new avenues for treating inflammatory diseases, including autoimmune and cardiovascular conditions.

SourceKarolinska Institutet·JournalProceedings of the National Academy of Sciences·DateMay 31, 2022